Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial.
Rha SY, Choueiri TK, Matveev VB, Alyasova A, Hong SH, Gordoa TA, Gurney H, Bjarnason GA, Buchler T, Pedrazzoli P, Takagi T, Park SH, Lee JL, Perini RF, He CS, McKenzie JA, Eto M. Rha SY, et al. Among authors: matveev vb. Int J Cancer. 2023 Sep 15;153(6):1241-1250. doi: 10.1002/ijc.34608. Epub 2023 Jun 9. Int J Cancer. 2023. PMID: 37294085 Clinical Trial.
The prominent role of the S100A8/S100A9-CD147 axis in the progression of penile cancer.
Mohr T, Zwick A, Hans MC, Bley IA, Braun FL, Khalmurzaev O, Matveev VB, Loertzer P, Pryalukhin A, Hartmann A, Geppert CI, Loertzer H, Wunderlich H, Naumann CM, Kalthoff H, Junker K, Smola S, Lohse S. Mohr T, et al. Among authors: matveev vb. Front Oncol. 2022 Oct 11;12:891511. doi: 10.3389/fonc.2022.891511. eCollection 2022. Front Oncol. 2022. PMID: 36303837 Free PMC article.
[Importance of HPV status and p16 for the prognosis of penile carcinoma].
Mink JN, Khalmurzaev O, Pryalukhin A, Hölters S, Geppert C, Lohse S, Bende K, Lobo J, Henrique R, Loertzer H, Steffens J, Jerónimo C, Wunderlich H, Heinzelbecker J, Bohle R, Stöckle M, Matveev V, Hartmann A, Junker K. Mink JN, et al. Aktuelle Urol. 2023 Aug;54(4):274-284. doi: 10.1055/a-2104-1270. Epub 2023 Aug 4. Aktuelle Urol. 2023. PMID: 37541236 German.
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.
Merseburger AS, Attard G, Åström L, Matveev VB, Bracarda S, Esen A, Feyerabend S, Senkus E, López-Brea Piqueras M, Boysen G, Gourgioti G, Martins K, Chowdhury S. Merseburger AS, et al. Among authors: matveev vb. Lancet Oncol. 2022 Nov;23(11):1398-1408. doi: 10.1016/S1470-2045(22)00560-5. Epub 2022 Oct 18. Lancet Oncol. 2022. PMID: 36265504 Clinical Trial.
Computer-aided Evaluation of Polyvalent Medications' Pharmacological Potential. Multiphytoadaptogen as a Case Study.
Bocharova OA, Ionov NS, Kazeev IV, Shevchenko VE, Bocharov EV, Karpova RV, Sheychenko OP, Aksyonov AA, Chulkova SV, Kucheryanu VG, Revishchin AV, Pavlova GV, Kosorukov VS, Filimonov DA, Lagunin AA, Matveev VB, Pyatigorskaya NV, Stilidi IS, Poroikov VV. Bocharova OA, et al. Among authors: matveev vb. Mol Inform. 2023 Jan;42(1):e2200176. doi: 10.1002/minf.202200176. Epub 2022 Oct 6. Mol Inform. 2023. PMID: 36075866
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
75 results